John Strohl

GATC Health Corp. is a technology company based in Irvine, CA that uses whole genome analysis and multiomics-based artificial intelligence to revolutionize disease detection and drug discovery. The company's validated and proprietary Multiomics Advanced Technology™ (MAT) platform simulates human biochemistry's billions of interactions for accurate and rapid disease prediction, novel target identification, and drug discovery and development. GATC Health envisions a future of medicine where health is protected, disease is reversed, and every person's unique biology is treated with precision. The CEO of the company is Jeff Moses.

GATC Health Corp. is a technology company based in Irvine, CA that uses whole genome analysis and multiomics-based artificial intelligence to revolutionize disease detection and drug discovery. The company's validated and proprietary Multiomics Advanced Technology™ (MAT) platform simulates human biochemistry's billions of interactions for accurate and rapid disease prediction, novel target identification, and drug discovery and development. GATC Health envisions a future of medicine where health is protected, disease is reversed, and every person's unique biology is treated with precision. The CEO of the company is Jeff Moses.

GATC Health Corp. is a technology company based in Irvine, CA that uses whole genome analysis and multiomics-based artificial intelligence to revolutionize disease detection and drug discovery. The company's validated and proprietary Multiomics Advanced Technology™ (MAT) platform simulates human biochemistry's billions of interactions for accurate and rapid disease prediction, novel target identification, and drug discovery and development. GATC Health envisions a future of medicine where health is protected, disease is reversed, and every person's unique biology is treated with precision. The CEO of the company is Jeff Moses.

GATC Health Corp. is a technology company based in Irvine, CA that uses whole genome analysis and multiomics-based artificial intelligence to revolutionize disease detection and drug discovery. The company's validated and proprietary Multiomics Advanced Technology™ (MAT) platform simulates human biochemistry's billions of interactions for accurate and rapid disease prediction, novel target identification, and drug discovery and development. GATC Health envisions a future of medicine where health is protected, disease is reversed, and every person's unique biology is treated with precision. The CEO of the company is Jeff Moses.